NCT06778512 LcProt: Proteomics Longitudinal Cohort Study on Lung Cancer
| NCT ID | NCT06778512 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The First Affiliated Hospital of Guangzhou Medical University |
| Condition | Lung |
| Study Type | OBSERVATIONAL |
| Enrollment | 2,500 participants |
| Start Date | 2019-06-01 |
| Primary Completion | 2026-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 2,500 participants in total. It began in 2019-06-01 with a primary completion date of 2026-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study will utilize tissue and peripheral blood samples for proteomics analysis and establish a longitudinal proteomics cohort at multiple critical treatment time points to explore the research value of proteomics in the diagnosis and treatment of lung cancer. The study includes key time points such as screening, postoperative efficacy prediction, and efficacy prediction after medication.
Eligibility Criteria
Inclusion Criteria: 1. Signing of the informed consent form; 2. Male or female, aged 18-75 years; 3. Patients with lung nodules confirmed by CT examination; 4. Good preoperative pulmonary function cooperation and complete reporting; 5. Preoperative chest single/dual phase CT scans without significant artefacts and with complete imaging; 6. The interval between preoperative pulmonary function and single/dual phase CT scans does not exceed one month. Exclusion Criteria: 1. Poor preoperative pulmonary function cooperation or missing reports; 2. Preoperative chest single/dual phase CT scans exhibit significant artefacts or image omission; 3. The interval between preoperative pulmonary function and single/dual phase CT scans exceeds one month; 4. Complication with severe respiratory disorders (such as lung transplantation, pneumothorax, giant bullae, etc.); 5. Coexisting with other severe functional impairments; 6. Patients with obstructive lesions such as airway or esophageal stenosis; (8) Medication use before pulmonary function testing that does not meet the cessation guidelines; (9) Pulmonary function report quality graded D-F.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06778512 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Lung. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06778512 currently recruiting?
Yes, NCT06778512 is actively recruiting participants. Contact the research team at drjiaxing.he@gmail.com for enrollment information.
Where is the NCT06778512 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT06778512 clinical trial?
NCT06778512 is sponsored by The First Affiliated Hospital of Guangzhou Medical University. The trial plans to enroll 2,500 participants.